Cytokinetics CYTK
NASDAQ CYTK
$65.91 +0.27 (+0.41%)
At close: Sep 30, 2026 · 4:00 PM EDT

Cytokinetics (CYTK) Gross Margin (2025 - 2026)

Updated

Cytokinetics (CYTK) recorded Gross Margin of 90.46% in Q2 2026, down 9.54 percentage points from 100.00% a year earlier and down 8.71 percentage points from the prior quarter.

Analysis

Cytokinetics (CYTK) Gross Margin (2025 - 2026) Analysis & Trends

On a TTM basis, Cytokinetics' Gross Margin came in at 167.63% as of Jun 30, 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 68.19%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 74.74%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 73.54%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 78.02%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 83.60%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 72.04%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 79.76%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 72.78%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 85.33%
10 Cytokinetics 9.16 Bn 5.33 Bn 25.89 Mn 90.46%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 90.46%
Mar 31, 2026 99.17%
Jun 30, 2025 100.00%
Mar 31, 2025 100.00%
API Access

Cytokinetics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=CYTK&period=max&api_key=YOUR_API_KEY